The data will be presented at the Annual ALS Drug Development Summit, which is focused on identifying transformative ALS targets, seeking translational biomarkers and propelling more clinical.
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn s® Phase 3 Clinical Trial in ALS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.
Conference call planned for early April 2024 to provide update on NurOwn program
NEW YORK, April 1, 2024 /PRNewswire/ BrainStorm Cell Therapeutics Inc. , a leading developer of adult stem cell.
Brainstorm Cell Therapeutics Announces Full Year 2023 Financial Results And Provides Corporate Update menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.